ResearcherLMU KlinikumActive in the last 2 years
Elisabetta Goni
Matched on ORCID iD 0000-0002-3094-9968; OpenAlex author ID A5071608393. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 7
- Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
- Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
- Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
- [Diabetes and pancreatic cancer - state of the art]. Last author DOI 10.1007/s15006-020-0428-5↗
- Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. First author DOI 10.1093/jncics/pkz060↗
- Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Julia V. Mayerle · 6 shared papers, 2018–2023 · strength 0.63
- Paper [Diabetes and pancreatic cancer - state of the art]. DOI 10.1007/s15006-020-0428-5↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Georg Beyer · 5 shared papers, 2018–2023 · strength 0.47
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells10071821↗
- Frank Ulrich Weiß · 4 shared papers, 2018–2022 · strength 0.34
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells10071821↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Markus M. Lerch · 4 shared papers, 2018–2022 · strength 0.34
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells10071821↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Ujjwal Mukund Mahajan · 4 shared papers, 2018–2022 · strength 0.34
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells10071821↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Simon Sirtl · 2 shared papers, 2020–2022 · strength 0.27
- Steffen Ormanns · 3 shared papers, 2018–2023 · strength 0.26
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Jan Goesta D’Haese · 3 shared papers, 2018–2023 · strength 0.26
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Jens Werner · 3 shared papers, 2018–2023 · strength 0.26
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Stefan Hubert Boeck · 3 shared papers, 2018–2023 · strength 0.26
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Ivonne Regel · 3 shared papers, 2018–2022 · strength 0.26
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cells10071821↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- John P. Neoptolemos · 3 shared papers, 2018–2022 · strength 0.24
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. DOI 10.1093/jncics/pkz060↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Volker Heinemann · 2 shared papers, 2020–2023 · strength 0.21
- Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.21
- Fritz Klein · 2 shared papers, 2021–2022 · strength 0.21
- Robert Grützmann · 2 shared papers, 2021–2022 · strength 0.21
- Christian P. Pilarsky · 2 shared papers, 2021–2022 · strength 0.21
- Marius Distler · 2 shared papers, 2021–2022 · strength 0.21
- Roland Rad · 2 shared papers, 2018–2022 · strength 0.16
- Paper Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic … DOI 10.1053/j.gastro.2022.07.047↗
- Paper Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal… DOI 10.1053/j.gastro.2018.08.009↗
- Markus Wolfgang Büchler · 2 shared papers, 2018–2020 · strength 0.13
- Stephan Krüger · 2 shared papers, 2018–2020 · strength 0.13
- William Greenhalf · 2 shared papers, 2018–2020 · strength 0.13
- Christopher Michael Halloran · 2 shared papers, 2018–2020 · strength 0.13
- Eithne Costello · 2 shared papers, 2018–2020 · strength 0.13
- Danmei Zhang · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.